tag:blogger.com,1999:blog-1394987738613999421.post6454773460730911086..comments2023-03-24T06:40:45.338-07:00Comments on Parkinson's Insights: Old Drugs – New Cures?Robin Elliotthttp://www.blogger.com/profile/10307317268932240843noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-1394987738613999421.post-37135905455879235392013-10-07T02:18:29.462-07:002013-10-07T02:18:29.462-07:00very good info, thanks for the article interesting...very good info, thanks for the article interestingkrokodil - desomorphinehttp://krocodildrug.blogspot.com/noreply@blogger.comtag:blogger.com,1999:blog-1394987738613999421.post-62624628616283434302013-08-26T07:35:26.284-07:002013-08-26T07:35:26.284-07:00Jim, I enjoyed reading "Old Drugs – New Cures...Jim, I enjoyed reading "Old Drugs – New Cures." I'm surprised that nilotinib did not get more interest. Although there is toxicity and side effects these are dose related and, as the Hopkins group noted, PD may respond to much lower doses. Moreover, there are many other TK inhibitors on the market or in the pipeline. As an oncologist who has used these drugs in CML, GIST tumors, and other solid tumors, I think the risk benefit is reasonable if efficacy can be established.<br /> Were calcium channel blockers discussed as well?<br /> Is it possible to see the report from the meeting?<br />TomThomas Shiftan M.D.noreply@blogger.com